- 4009 Hackney Springs Ln, Sachse, TX 75048
If you’ve spent any real time inside a laboratory billing department, you already know the problem this article solves. Someone hands a new hire a denial report, and the report might as well be written in a foreign language. CO-16. PR-204. ABN. CLIA-exempt. Modifier 91. MUE. TPE. The new hire nods, writes something down, and quietly searches half of it after the meeting ends.
That’s not a knock on anyone. Laboratory billing sits at the intersection of several languages that don’t naturally overlap: clinical medicine, insurance administration, federal compliance law, health IT data standards, and increasingly, molecular science. Each one brings its own vocabulary, and none of them were designed with the others in mind. Miss a term, misread a code, or confuse two similarly named concepts, and the result isn’t just an awkward moment in a training session. It’s a rejected claim, a compliance flag, an audit finding, or a patient who receives a bill they should never have gotten.
I built this reference after two decades in laboratory revenue cycle work, across independent reference labs, hospital outreach labs, physician office labs, and molecular diagnostics companies. The terms below are not academic. Every one of them is something I have personally watched a billing team either master and turn into recovered revenue, or misunderstand and turn into a write-off, a denial cycle, or a compliance headache. This guide is organized the way I would actually walk a new analyst through the revenue cycle: coding and documentation first, then claims submission, reimbursement mechanics, compliance and regulatory law, denial management, audits and program integrity, patient financial responsibility, specimen and operational workflow, the technology layer that moves all of this data, and finally the specialty and molecular testing terms that are reshaping the field right now.
This is a long article by design. Laboratory billing terminology is not a short list, and an article that pretends otherwise isn’t actually useful to the people who need it like new hires building fluency, experienced billers filling gaps, compliance officers training staff, or lab directors trying to understand what their own billing department is talking about in a meeting. Bookmark it, or drop it into your onboarding materials. It’s meant to be used, not skimmed once.
These are the building blocks of every claim. Get these wrong at the front end, and every downstream step such as claims, payments and audits, etc. inherits the error.
CPT Code (Current Procedural Terminology) — A five-digit code maintained by the American Medical Association identifying the specific lab test performed. Lab-relevant CPT codes generally fall in the 80047–89398 range, covering everything from a basic metabolic panel (80048) to advanced molecular pathology procedures. Every claim line requires one.
ICD-10-CM Code — The diagnosis code answering the question of why a test was ordered. Labs generally don’t diagnose; they report the ordering provider’s stated clinical reason. A mismatch between the CPT code billed and the ICD-10 code submitted is one of the most common sources of medical necessity denials.
HCPCS Level II Code — A code set covering items and services CPT doesn’t address, including certain lab-related supplies, some genetic tests, and services billed to Medicare that fall outside standard CPT categories.
Modifier (general) — A two-character code appended to a CPT code to clarify circumstances without changing the underlying service definition. Modifiers are frequently the deciding factor in whether a payer processes two related codes as separate, billable services or bundles them into one.
Modifier 91 — Indicates a repeat clinical diagnostic lab test performed on the same patient, same day, for a medically necessary reason, not a duplicate billing error. Commonly used for serial glucose or troponin testing.
Modifier 59 — Signals a distinct procedural service, used to unbundle two codes that would otherwise be denied as included in one another. Overuse of Modifier 59 is a frequent audit target because it can be misapplied to bypass legitimate bundling edits.
Modifier QW — Identifies a CLIA-waived test. Required on many Medicare claims for point-of-care and physician office lab testing performed under a CLIA Certificate of Waiver.
Modifier 26 (Professional Component) — Used when billing only for the physician interpretation portion of a test, separate from the technical component. Common in anatomic pathology when the interpreting pathologist and the lab performing the technical work are different entities.
Modifier TC (Technical Component) — The counterpart to Modifier 26, used when billing only for the equipment, technician labor, and supplies involved in performing a test, without the professional interpretation.
Global vs. Component Billing — A ‘global’ claim bills both the technical and professional components together under one code with no modifier; ‘component’ billing splits them using Modifier 26 and Modifier TC when different entities perform each part. Choosing the wrong billing structure is a frequent source of overpayment and compliance risk in pathology billing.
NCCI Edits (National Correct Coding Initiative) — CMS-maintained edits flagging code combinations considered improperly bundled or mutually exclusive. If two CPT codes hit an NCCI edit and no modifier justifies separate billing, one line will deny automatically.
MUE (Medically Unlikely Edit) — A CMS edit that caps the number of units of a given CPT code that can reasonably be billed for one patient on one date of service. Exceeding an MUE without documentation supporting medical necessity for the extra units triggers an automatic denial.
Panel Code — A single CPT code representing a defined bundle of individual tests, for example, the Comprehensive Metabolic Panel (CPT 80053) bundles 14 individual chemistry tests. Billing the individual component tests separately instead of the panel code, sometimes called unbundling, is a compliance red flag payers actively audit.
Reflex Testing — A workflow in which an initial test result automatically triggers a follow-up test under a pre-established protocol, without a new physician order. Reflex tests require careful documentation because payers scrutinize whether the reflex was genuinely automatic and clinically justified, rather than billed as though separately ordered.
Add-On Code — A CPT code that can only be billed in conjunction with a specific primary procedure code, never on its own. Add-on codes are exempt from certain multiple-procedure payment reductions but still require the primary code to be present on the same claim.
Category I, II, and III CPT Codes — Category I codes are the standard, widely reimbursed procedure codes. Category II codes are supplemental tracking codes used for performance measurement, not separately reimbursed. Category III codes are temporary codes for emerging technology and services, often used before a permanent code exists, and typically carry inconsistent payer coverage.
PLA Code (Proprietary Laboratory Analysis) — A CPT code category specifically for proprietary, single-source laboratory tests, often branded assays developed by a specific lab or manufacturer. PLA codes exist to give proprietary tests a distinct, trackable billing identity separate from generic Tier 1 or Tier 2 molecular codes.
Tier 1 / Tier 2 Molecular Pathology Codes — Tier 1 codes are specific, named genetic tests (for example, BRCA1 analysis). Tier 2 codes are stratified by technical complexity level for genetic tests that don’t have a dedicated Tier 1 code. Correctly distinguishing Tier 1 from Tier 2 billing is a frequent source of molecular claim denials.
Z-Code Identifier — A unique identifier assigned by the McKesson Diagnostics Exchange (DEX) registry to specific molecular and genetic tests, used primarily by MolDx-participating Medicare contractors to determine coverage and correct claim adjudication for otherwise ambiguous molecular CPT codes.
Units of Service — The quantity of a given CPT code billed on a claim line, which must accurately reflect how many times a test or component was actually performed. Overstating units of service, even unintentionally, is treated as a billing error subject to recoupment.
Frequency Limitation — A payer policy restricting how often a specific test can be billed for the same patient within a defined time period, regardless of medical necessity documentation, unless an exception applies.
Bundling vs. Unbundling — Bundling refers to the correct practice of billing a panel or combination code when its component tests are performed together. Unbundling refers to improperly billing those same components separately to generate higher reimbursement; a practice that is both a compliance violation and a common trigger for post-payment audits.
LOINC Code (Logical Observation Identifiers Names and Codes) — A standardized code used mainly for laboratory result reporting and system interoperability, distinct from CPT billing codes. Not typically used for billing itself, but increasingly required for EHR integration and value-based care reporting.
Charge Description Master (CDM / Chargemaster) — The internal master list is a document that a lab or hospital maintains of every billable service, its associated CPT/HCPCS code, and its list price. An outdated or misaligned chargemaster is a leading root cause of systemic coding and billing errors across an entire lab.
NDC (National Drug Code) — An 11-digit code identifying a specific drug product, required on some laboratory claims involving reagents or drug-based testing components, particularly for certain toxicology and pharmacogenomic billing scenarios.
Diagnosis Pointer — The field on a claim line linking a specific CPT code to the specific ICD-10 code(s) on the claim that justify it. An incorrect diagnosis pointer can cause a payer to evaluate medical necessity against the wrong diagnosis entirely, resulting in an avoidable denial.
Once documentation and coding are finalized, the claim enters the submission pipeline. This section covers the mechanics of getting a claim from the lab’s system into a payer’s adjudication system correctly the first time.
Clean Claim — A claim submitted with no errors that can be processed without requesting additional information from the provider. Clean claim rate is one of the most important KPIs in any billing operation, since every percentage point of improvement translates directly into faster cash flow.
Clearinghouse — A third-party intermediary that scrubs claims for formatting errors, translates them into the standardized ASC X12 837 format, and routes them to the correct payer. Most labs never submit claims directly to a payer; the clearinghouse sits in between.
837 and 835 (ASC X12 Transaction Sets) — The 837 is the standardized electronic claim submission format. The 835 is the electronic remittance advice, the payer’s structured response showing what was paid, adjusted, or denied. Both are federally mandated formats under HIPAA transaction standards.
Claim Scrubber — Software, often part of the billing system or clearinghouse, that automatically checks claims against payer-specific and NCCI rules before submission, catching errors that would otherwise cause a rejection or denial.
Batch Submission vs. Real-Time Submission — Batch submission sends groups of claims together on a schedule, typically once or twice daily. Real-time submission sends and often receives adjudication feedback on individual claims immediately. Most high-volume lab billing still relies primarily on batch processing due to claim volume.
Claim Frequency Code — A field on the claim indicating whether it is an original submission, a corrected replacement of a prior claim, or a void of a prior claim. Submitting a correction without the proper frequency code frequently causes the payer to reject it as a duplicate.
Payer ID — A unique identifier assigned to each insurance payer, used by clearinghouses and billing systems to route claims to the correct destination. An incorrect payer ID is one of the most common causes of claim rejection before a claim ever reaches adjudication.
NPI (National Provider Identifier) — A unique 10-digit identifier assigned to healthcare providers and organizations, required on virtually every claim. Labs typically use both a Type 2 (organizational) NPI for the billing entity and, where relevant, individual NPIs for ordering or interpreting providers.
Taxonomy Code — A code identifying a provider’s specific specialty or type of practice, submitted alongside the NPI on claims. Certain payers use taxonomy codes to determine appropriate reimbursement rates or coverage rules for a given claim.
Place of Service (POS) Code — A two-digit code indicating where a service was rendered, for example, 11 for a physician office, 81 for an independent laboratory. An incorrect POS code can trigger a denial even when the underlying test and diagnosis are entirely appropriate.
Type of Bill — A code used primarily in institutional (hospital-based or outreach) billing indicating the type of facility and billing frequency. Distinct from POS codes, which are used on professional claims.
Assignment of Benefits — A patient’s authorization allowing the payer to send reimbursement directly to the provider rather than to the patient. Without assignment of benefits on file, a lab may find itself waiting on the patient to forward a payment the payer sent to them directly.
Crossover Claim — A claim that automatically transfers from a primary payer, most often Medicare, to a secondary payer without requiring separate submission by the provider. Crossover failures are a common and frustrating source of secondary-payer denials.
Eligibility Verification / 270-271 Transaction — The process of confirming a patient’s active insurance coverage before or at the time of service, conducted electronically through the 270 (eligibility inquiry) and 271 (eligibility response) transaction set. Skipping eligibility verification is one of the single largest preventable causes of denied lab claims.
Prior Authorization — Payer approval required before certain tests are performed, confirming in advance that the service will be covered. Increasingly required for molecular, genetic, and some specialty chemistry testing.
Predetermination — A voluntary, non-binding request to a payer for an estimate of coverage and payment before a service is rendered, distinct from prior authorization in that it is not typically a coverage requirement, only an informational estimate.
Superbill / Encounter Form — A structured form or system record capturing the diagnosis, procedures performed, and provider information for a given patient encounter, used as the source document for claim generation.
Charge Capture — The internal process of ensuring every billable test performed is actually recorded and transmitted to the billing system for claim generation. Gaps in charge capture like tests performed but never billed, represent pure, permanently lost revenue with no denial code to chase.
Days Sales Outstanding (DSO) — A revenue cycle metric measuring the average number of days it takes to collect payment after a claim is billed. Rising DSO is often the earliest warning sign of a growing claims-processing or denial problem.
Once a claim is accepted for processing, these are the terms describing how a payer actually determines and delivers payment.
EOB (Explanation of Benefits) — The document a payer sends to the patient summarizing what was billed, what was covered, and what the patient owes. Frequently confused with the ERA, which serves the provider rather than the patient.
ERA (Electronic Remittance Advice) — The provider-facing equivalent of an EOB, derived from the 835 transaction set. This is the document billing staff actually work from when posting payments and researching denials.
Allowed Amount — The maximum amount a payer will reimburse for a given service under a patient’s specific plan, regardless of what was billed. The difference between the billed charge and the allowed amount is typically a contractual adjustment, not something the patient owes, unless out-of-network rules apply.
Fee Schedule — The rate table a payer uses to determine allowed amounts for covered services.
CLFS (Clinical Laboratory Fee Schedule) — The Medicare fee schedule specifically governing reimbursement for most clinical laboratory tests. It functions as the benchmark that many commercial payers reference, directly or indirectly, when setting their own lab rates.
PAMA (Protecting Access to Medicare Act) — Federal legislation that fundamentally changed how CLFS rates are set, requiring applicable labs to report private payer payment rates so Medicare rates can be adjusted to reflect actual market pricing. PAMA-driven rate cuts have been one of the most significant financial pressures on the lab industry over the past decade.
Gapfill Process — A CMS process used to establish a new CLFS payment rate for a test that doesn’t have an existing comparable code, based on local Medicare Administrative Contractor recommendations before a national rate is finalized.
Crosswalk Process — A CMS process assigning a new CPT code a payment rate based on an existing, comparable test’s rate, used as an alternative to gapfilling when a sufficiently similar test already exists on the fee schedule.
Contractual Adjustment — The portion of a billed charge that a provider is contractually obligated to write off under its agreement with a payer, representing the gap between the billed charge and the negotiated allowed amount.
Par vs. Non-Par Provider — A ‘participating’ (par) provider has a contract with the payer and agrees to accept the negotiated allowed amount as payment in full. A ‘non-participating’ (non-par) provider has no such contract and may be able to bill patients for more than the allowed amount, depending on state and federal balance billing rules.
Balance Billing — The practice of billing a patient for the difference between what a provider charged and what insurance paid, now heavily restricted for many services under the federal No Surprises Act, though rules vary by service type and payer network status.
Capitation — A reimbursement model paying a fixed amount per patient per period, regardless of how many services are actually rendered, as opposed to traditional fee-for-service billing. Uncommon for standalone lab billing but relevant in value-based and risk-sharing contracts.
Fee-for-Service — The traditional reimbursement model in which a provider is paid for each individual service rendered, which remains the dominant model for most laboratory billing.
RVU (Relative Value Unit) — A standardized measure of the resources required to perform a given service, used by CMS to help calculate fee schedule payment amounts. Less central to lab billing than physician billing, but relevant for professional-component pathology services.
Coordination of Benefits (COB) — The process of determining which payer is primary when a patient has more than one insurance plan. Getting COB wrong is a leading cause of delayed lab payments, since a secondary payer will reject a claim that should have gone to the primary payer first.
This is the category where mistakes carry the highest stakes: not just lost revenue, but regulatory exposure, exclusion risk, and in serious cases, criminal liability.
CLIA (Clinical Laboratory Improvement Amendments) — The federal law and certification framework governing laboratory testing quality standards. A lab’s CLIA certificate number must appear on claims, and its certificate type such as waived, provider-performed microscopy, or moderate/high complexity, determines which tests it may legally perform and bill.
Medical Necessity — The standard requiring that a test be reasonable and necessary for the diagnosis or treatment of a patient’s condition according to payer coverage policy, not simply because a physician ordered it. This is the single most frequent root cause of laboratory claim denials industry-wide.
LCD (Local Coverage Determination) and NCD (National Coverage Determination) — Formal Medicare policies defining whether and under what circumstances a specific test is covered. LCDs are issued regionally by Medicare Administrative Contractors and vary by jurisdiction; NCDs apply nationwide. Labs bill against these policies constantly, especially for molecular and genetic testing.
ABN (Advance Beneficiary Notice of Non-Coverage) — A form given to a Medicare patient before a service is performed, when the lab has reason to believe Medicare may not cover it. Without a valid, properly executed ABN on file, a lab generally cannot bill the patient if Medicare denies the claim for medical necessity, making the write-off mandatory rather than optional.
Anti-Markup Rule — A regulation preventing a billing entity from marking up the price of a purchased or referred lab test above its actual cost under certain billing arrangements, particularly relevant for reference lab relationships and physician office labs.
Stark Law (Physician Self-Referral Law) — A federal law restricting physicians from referring patients for designated health services, including many lab tests, to entities in which the physician has a financial relationship, unless a specific exception applies.
Anti-Kickback Statute — A federal criminal law prohibiting the exchange of anything of value intended to induce referrals of services reimbursable by federal healthcare programs. Lab specimen collection fees, discounts, and marketing arrangements are frequent areas of Anti-Kickback scrutiny.
EKRA (Eliminating Kickbacks in Recovery Act) — A federal law originally aimed at addiction treatment referral fraud that also applies broadly to clinical laboratories, prohibiting certain compensation arrangements tied to referrals, including some commission-based sales models that would otherwise be permissible under Anti-Kickback Statute safe harbors.
False Claims Act (FCA) — A federal law imposing civil liability for knowingly submitting false or fraudulent claims to government healthcare programs. Many lab billing compliance programs exist specifically to prevent the patterns like upcoding, unbundling, medically unnecessary testing — that most commonly trigger FCA liability.
Qui Tam — A provision of the False Claims Act allowing private individuals, often current or former employees, to file suit on behalf of the government against an entity they believe committed fraud, and to share in any resulting recovery. A significant share of major lab billing fraud cases originate as qui tam whistleblower actions.
Safe Harbor — A specific set of conditions under the Anti-Kickback Statute that, if fully satisfied, protects an arrangement from prosecution even though it might otherwise appear to violate the statute. Lab compliance counsel spends considerable time structuring specimen collection and consulting arrangements to fit within recognized safe harbors.
HIPAA (Health Insurance Portability and Accountability Act) — Federal law governing the privacy and security of patient health information, as well as establishing the standardized electronic transaction formats, including the 837 and 835, used throughout the billing process.
Minimum Necessary Standard — A HIPAA principle requiring that only the minimum amount of protected health information necessary to accomplish a given purpose be used or disclosed, relevant when billing staff access patient records for claims and appeals work.
Upcoding — Billing for a more complex or higher-reimbursing service than was actually performed. One of the most heavily scrutinized compliance risks in lab billing, particularly around panel versus individual component billing.
Downcoding — The reverse of upcoding: billing for a less complex or lower-reimbursing service than was actually performed, sometimes done by payers unilaterally during adjudication, which providers can and should appeal when unsupported.
Duplicate Billing — Submitting more than one claim for the same service, same patient, same date, without a legitimate clinical reason such as a repeat test properly modified with Modifier 91. A frequent, avoidable denial category and, if habitual, a compliance concern.
Proficiency Testing — A CLIA-mandated program requiring labs to periodically test known samples and report results for external evaluation, verifying the lab’s ongoing testing accuracy. Directly tied to a lab’s continued eligibility to bill for the tests it performs.
CAP Accreditation — Accreditation from the College of American Pathologists, a common voluntary quality standard that satisfies CLIA requirements and is often required by payers or referring institutions as a condition of participation.
Medical Director Attestation — A requirement that a lab’s designated medical director formally attest to oversight responsibilities for testing performed under the lab’s CLIA certificate, a role directly tied to both quality compliance and billing integrity for high-complexity testing.
Date of Service (DOS) vs. Date of Report — The distinction between when a specimen was collected (date of service) and when results were finalized (date of report). Billing under the wrong date is a common, avoidable error that can trigger both denials and compliance concerns.
Client Bill / Split Billing — An arrangement in which a physician’s office pays the lab directly for testing, often at a negotiated rate, rather than the lab billing the patient’s insurance directly. Heavily regulated, and depending on structure, can raise Anti-Markup or Anti-Kickback concerns if not carefully documented.
Self-Referral — A referral by a physician for lab services in which the physician or an immediate family member has a financial relationship with the lab, directly implicating Stark Law unless a valid exception applies.
No Surprises Act — Federal legislation, effective 2022, restricting balance billing for out-of-network services in many circumstances and requiring Good Faith Estimates for uninsured and self-pay patients, with direct implications for how labs bill patients for out-of-network and self-pay testing.
This is where billing teams either recover revenue that’s rightfully owed or leave it on the table permanently.
CARC (Claim Adjustment Reason Code) — A standardized code explaining why a claim was adjusted or denied, for example, CO-50 indicates the service is not deemed a medical necessity by the payer.
RARC (Remittance Advice Remark Code) — A supplemental code adding detail to a CARC, often clarifying exactly what documentation or corrective action is needed. CARCs and RARCs are meant to be read together; reading only one is like reading half a sentence.
Claim Adjustment Group Codes (CO, PR, OA, PI) — The prefix attached to a CARC telling you who is responsible for the adjustment. CO means Contractual Obligation, a provider write-off the patient cannot be billed for. PR means Patient Responsibility, which can be billed to the patient. OA means Other Adjustment. PI means Payer Initiated reduction.
Denial vs. Rejection — A rejection happens before adjudication, the claim never entered the payer’s processing system due to a formatting or eligibility error. A denial happens after adjudication, the claim was reviewed and a decision was made not to pay it. The correction path differs completely between the two.
Appeal — A formal request for a payer to reconsider a denial, typically requiring supporting documentation such as medical records, an ABN, or a letter of medical necessity. Most payers allow multiple levels of appeal, each with strict filing deadlines.
Redetermination (Medicare Appeal Level 1) — The first level of the Medicare appeals process, a request that the Medicare Administrative Contractor that processed the original claim reconsider its decision, typically required within 120 days of the denial notice.
Reconsideration (Medicare Appeal Level 2) — The second level of Medicare appeal, conducted by a Qualified Independent Contractor, pursued when a redetermination is unfavorable.
ALJ Hearing (Medicare Appeal Level 3) — A hearing before an Administrative Law Judge, available once a minimum dollar threshold is met, pursued after an unfavorable reconsideration decision.
Departmental Appeals Board Review (Medicare Appeal Level 4) — A review by the Medicare Appeals Council of an unfavorable ALJ decision, the fourth level in the federal Medicare appeals structure.
Federal Court Review (Medicare Appeal Level 5) — The final level of Medicare appeal, involving judicial review in federal district court, reserved for claims meeting a substantial dollar threshold and typically pursued only for high-value, precedent-setting disputes.
Corrected Claim vs. Resubmission — A corrected claim replaces an original claim with fixed information and must carry the proper claim frequency code so the payer treats it as a correction, not a duplicate. Submitting a fix as a brand-new claim without this flag frequently triggers an automatic duplicate denial.
Timely Filing Limit — The payer-specific deadline within which a claim must be submitted or it is automatically denied, generally with no exceptions. Limits range from 90 days to a year depending on the payer, making this one of the least forgivable denial categories because it is entirely avoidable with good claim aging management.
Write-Off — The portion of a charge a lab formally removes from accounts receivable because it will not be collected, whether due to a contractual adjustment, an uncollectible patient balance, or a compliance-driven adjustment like an unsigned ABN.
Aging Report / AR Aging — A report categorizing outstanding claims by how long they have been unpaid, typically in 0–30, 31–60, 61–90, and 90-plus day buckets. This is the primary tool billing managers use to catch timely filing risk before it becomes a permanently lost claim.
Clean Claim Rate — The percentage of claims that process successfully without requiring correction or manual intervention. Widely regarded as the single best leading indicator of overall billing department health.
First-Pass Resolution Rate — The percentage of claims paid correctly on the very first submission, without requiring an appeal, correction, or resubmission of any kind.
Denial Rate — The percentage of submitted claims that come back denied rather than paid, tracked overall and by denial category to identify systemic problems in coding, documentation, or eligibility verification.
Root Cause Analysis (Denial Context) — The practice of tracing a denial back to its true originating error like a coding mistake, an eligibility gap, a missing ABN, rather than simply correcting and resubmitting the claim without addressing the underlying process failure.
Underpayment — A payment received that is less than what the payer’s own contract or fee schedule actually specifies for the service billed, often discovered only through systematic contract-rate auditing rather than routine payment posting.
Overpayment Recoupment — The process by which a payer reclaims funds it determines were paid in error, either by direct refund request or by withholding the amount from future claim payments.
Beyond routine claim denials, labs operate under an active audit and enforcement environment. These are the terms that come up when a claim’s history gets scrutinized after the fact.
OIG Work Plan — An annually updated public document from the Department of Health and Human Services Office of Inspector General outlining planned audits and investigations, frequently signaling which lab billing practices are drawing federal scrutiny that year.
RAC (Recovery Audit Contractor) — A CMS contractor paid on a contingency basis to identify improper Medicare payments, including both overpayments and underpayments, through post-payment claim review.
ZPIC / UPIC (Zone/Unified Program Integrity Contractor) — CMS contractors focused specifically on identifying potential fraud, as opposed to routine payment errors, often initiating more intensive investigations that can lead to payment suspension while under review.
TPE (Targeted Probe and Educate) — A CMS program in which a Medicare Administrative Contractor reviews a small sample of a provider’s claims, provides individualized education on any errors found, and allows the provider to improve before broader, more punitive review escalates.
Prepayment Review — A review process in which a payer evaluates supporting documentation before paying a claim, rather than after, typically triggered by a pattern of prior errors or unusual billing volume.
Post-Payment Audit — A review of claims that have already been paid, used to identify overpayments for recoupment or to build a broader fraud investigation.
Extrapolation — A statistical method auditors use to apply the error rate found in a small sample of claims to a much larger universe of claims, potentially resulting in a repayment demand far larger than the sample itself would suggest.
Voluntary Refund / Self-Disclosure — A proactive report and repayment a provider makes to a payer or the OIG upon discovering a billing error on its own, generally treated far more favorably than an error discovered through external audit.
Corporate Integrity Agreement (CIA) — A formal, multi-year compliance oversight agreement imposed on a provider as part of a settlement with the federal government, typically requiring independent monitoring, regular reporting, and enhanced internal auditing.
Comparative Billing Report (CBR) — A report comparing a specific provider’s billing patterns against national or regional peer averages for a given service, used to flag potential outliers before a more formal audit begins.
The terms your patient-facing staff need fluently, because these are the words patients actually hear and ask about.
Deductible — The amount a patient must pay out of pocket before insurance begins covering costs for the plan year.
Coinsurance — The percentage of the allowed amount a patient owes after the deductible is met, for example, 20% coinsurance on an $80 allowed amount means the patient owes $16.
Copay — A fixed dollar amount a patient owes for a covered service, independent of the total cost, less common for lab services specifically but still seen in some plan designs.
Out-of-Pocket Maximum — The ceiling on what a patient will pay in a plan year across deductible, coinsurance, and copay combined, after which the plan pays 100% of covered services.
Patient Statement — The bill sent directly to the patient for their portion of financial responsibility after insurance has adjudicated the claim, distinct from an EOB, which is informational rather than a bill.
Good Faith Estimate — Under the No Surprises Act, a required estimate of expected charges given to uninsured or self-pay patients before non-emergency services, including many lab tests.
Qualifying Payment Amount (QPA) — A benchmark payment amount used under the No Surprises Act to determine cost-sharing for certain out-of-network services and to serve as a starting reference point in independent dispute resolution.
Independent Dispute Resolution (IDR) — A formal arbitration process created under the No Surprises Act allowing providers and payers to resolve payment disputes for certain out-of-network services without involving the patient in the dispute.
Financial Hardship / Charity Care Policy — A lab’s formal, written policy for reducing or waiving patient financial responsibility based on documented income or hardship criteria, often required for nonprofit or hospital-affiliated labs.
Sliding Fee Scale — A structured discount schedule adjusting what a patient owes based on income level relative to federal poverty guidelines, common in community health and safety-net-affiliated laboratory arrangements.
Self-Pay Discount — A reduced rate offered to patients without insurance coverage, distinct from a contractual adjustment since no payer contract governs the reduction.
Bad Debt — A patient balance the lab has determined is uncollectible and writes off as a loss, distinct from a contractual adjustment or a charity care write-off, both of which follow different accounting and compliance treatment.
Payment Plan — A structured arrangement allowing a patient to pay their balance over time in installments rather than in a single payment.
Statement Cycle — The recurring schedule on which patient statements are generated and mailed or delivered electronically, typically every 30 days until a balance is resolved or moved to collections.
Patient Portal / Online Bill Pay — A digital platform allowing patients to view statements, make payments, and sometimes review test-related billing information directly, increasingly expected as a standard part of the patient’s financial experience.
Billing doesn’t start with a claim, it starts with a specimen. These operational terms directly affect whether the eventual claim will even be billable correctly.
Chain of Custody — The documented, unbroken record of a specimen’s handling from collection through final result, particularly critical for forensic, toxicology, and legally sensitive testing. A broken chain of custody can make a test result, and therefore the associated claim, indefensible under audit or legal challenge.
Specimen Accession — The process of formally logging a specimen into the lab’s system upon receipt, assigning it a unique identifying number that links it through testing, reporting, and billing.
Requisition Form — The order document, paper or electronic, submitted by the ordering provider specifying the tests requested and the clinical diagnosis or reason for testing. An incomplete or illegible requisition is a frequent root cause of medical necessity denials traced all the way back to the point of order.
Standing Order — A pre-authorized, recurring order allowing a patient to receive a specific test or panel repeatedly over a defined period without a new physician order each time, common for chronic disease monitoring.
STAT Testing — Testing performed and reported on an urgent, expedited basis, typically for acute clinical situations. STAT status itself doesn’t change billing rules, but the associated documentation and turnaround expectations differ from routine testing.
Send-Out Test / Reference Lab — A test that the ordering or performing lab does not have the capability to run in-house and instead forwards to a specialized reference lab. Billing responsibility for send-out tests depends heavily on the contractual arrangement between the two labs.
Referring Lab vs. Performing Lab — The referring lab is the entity that received the original specimen order; the performing lab is the entity that actually conducts the test. Medicare generally requires the performing lab to bill directly rather than through the referring lab, with limited exceptions.
Pass-Through Billing — A prohibited or heavily restricted practice in which a referring lab bills for a test actually performed by a different lab, without disclosing that the test was referred out, generally impermissible under Medicare rules absent a qualifying exception.
Courier Manifest — The tracking log documenting specimen pickup, transport, and delivery between collection sites and the performing lab, which supports both specimen integrity documentation and operational billing reconciliation.
Specimen Rejection — A determination that a received specimen cannot be tested due to quality issues such as insufficient volume, hemolysis, improper labeling, or expired collection. Specimen rejection directly affects billing because a test that was never performed cannot be legitimately billed, and any associated collection fee may or may not be recoverable depending on payer policy.
Turnaround Time (TAT) — The elapsed time between specimen receipt and final result reporting. While primarily an operational quality metric, TAT can affect billing indirectly through STAT fee eligibility and payer-specific timeliness requirements for certain test categories.
Retention Sample — A specimen or aliquot retained after initial testing to allow for repeat testing, add-on testing, or quality verification within a defined retention window, relevant when billing add-on tests ordered after the original result is already reported.
Every claim, eligibility check, and remittance moves through a defined data infrastructure. Understanding this layer helps billing staff troubleshoot problems that have nothing to do with coding and everything to do with data transmission.
LIS (Laboratory Information System) — The core software system managing specimen tracking, testing workflow, and results reporting within a lab, which typically feeds charge data into the billing system through an interface.
HL7 Interface — A standardized messaging format used to exchange clinical data, such as orders and results, between systems like an LIS and an electronic health record. HL7 interface errors are a frequent, and frequently overlooked, cause of charge capture gaps.
EDI (Electronic Data Interchange) — The broader category of standardized electronic transaction formats used throughout healthcare billing, including the 837, 835, 270/271, and 276/277 transaction sets.
270/271 Transaction (Eligibility Inquiry and Response) — The standardized electronic format for checking a patient’s insurance eligibility and benefits in real time before or at the time of service.
276/277 Transaction (Claim Status Inquiry and Response) — The standardized electronic format for checking the current processing status of a previously submitted claim, allowing billing staff to track a claim’s progress without a phone call to the payer.
Payer Portal — A payer-specific web application allowing providers to check eligibility, claim status, submit appeals, and access remittance information directly, often used as a supplement to standard EDI transactions.
Real-Time Adjudication — A claims processing capability in which a payer evaluates and returns a payment decision on a claim immediately at the point of submission, rather than through a batch process, still relatively uncommon for high-volume lab claims.
Claim Status Category Code — A standardized code returned in a 277 transaction indicating the general status of a claim, such as pending, finalized, or additional information required.
Interface Engine — Middleware software that manages and translates data flowing between multiple systems, such as an LIS, EHR, and billing platform, ensuring each system receives data in the format it requires.
API-Based Eligibility Check — A newer method of real-time eligibility verification using direct application programming interface connections to payer systems, increasingly used alongside or instead of traditional 270/271 batch transactions for faster point-of-service verification.
Molecular diagnostics, genetic testing, and toxicology represent the fastest-growing and most billing-complex segment of laboratory medicine. These terms are essential for any lab operating in this space.
Molecular Diagnostics Billing — The billing discipline covering genetic, genomic, and molecular pathology testing, which involves substantially more coverage variability, prior authorization requirements, and coding complexity than routine chemistry or hematology testing.
MolDx Program — A molecular diagnostics program administered by certain Medicare Administrative Contractors that establishes coverage, coding, and technical assessment requirements specifically for molecular tests, including the Z-Code registration system.
Definitive Drug Testing vs. Presumptive Drug Testing — Presumptive testing provides a preliminary positive or negative result, typically through immunoassay methods. Definitive testing identifies and quantifies specific substances, typically through mass spectrometry, and is billed under different codes with different medical necessity standards. Confusing the two is a leading cause of toxicology claim denials.
Genetic Counseling Modifier / Requirement — A documentation requirement, and in some payer policies a coverage prerequisite, that a patient receive genetic counseling before certain hereditary genetic tests are covered, intended to ensure informed consent and appropriate test selection.
Companion Diagnostic — A test specifically linked to determining a patient’s eligibility for a particular targeted drug therapy, often billed and reviewed under different medical necessity frameworks than standalone diagnostic testing.
MAAA (Multi-Analyte Assay with Algorithmic Analysis) — A CPT code category for tests that combine multiple test results with an algorithm to produce a single, often proprietary, clinical score or risk assessment, common in oncology and cardiology risk-stratification testing.
Liquid Biopsy Billing — Billing for blood-based tests analyzing circulating tumor DNA or cells as an alternative to traditional tissue biopsy, an area with still-evolving payer coverage policy and correspondingly high denial rates relative to established testing.
Send-Out Genetic Test Billing — The billing arrangement when a genetic test is referred to a specialized reference lab, which typically must bill directly under Medicare rules rather than through the referring provider or lab, with the referring party’s role limited to specimen collection and result reporting.
Medical Necessity for Genetic Testing (Prior Authorization Nuance) — Genetic and molecular tests are disproportionately subject to prior authorization and detailed medical necessity documentation requirements compared to routine lab testing, often requiring family history documentation, prior test results, and specific clinical criteria before a payer will approve coverage.
Pharmacogenomics Billing — Billing for testing that analyzes how a patient’s genetic makeup affects their response to specific medications, an emerging category with inconsistent payer coverage policies that billing teams must track closely by individual payer and test.
A handful of regulatory distinctions come up so frequently in day-to-day billing decisions that they warrant their own dedicated section rather than a single combined entry.
Certificate of Waiver — A CLIA certificate type authorizing a facility to perform only tests categorized as simple and low-risk for erroneous results, such as basic glucose or urine dipstick testing. Billing for a non-waived test under a waiver certificate is a serious compliance violation, not merely a documentation gap.
Certificate for Provider-Performed Microscopy Procedures (PPMP) — A CLIA certificate type permitting a limited set of microscopy procedures performed personally by a licensed provider, such as wet mount preparations, in addition to waived testing.
Certificate of Compliance — A CLIA certificate type for facilities performing moderate or high complexity testing that undergo routine on-site inspection by a state agency or CMS, rather than through a private accrediting organization.
Certificate of Accreditation — A CLIA certificate type for facilities performing moderate or high complexity testing that instead meet CLIA requirements through inspection by a CMS-approved private accrediting organization, such as CAP or the Joint Commission.
Order of Benefit Determination Rules — The specific set of rules, which vary by state and plan type, used to establish which of a patient’s multiple insurance plans pays first when coordinating benefits; for example, the birthday rule for dependent children covered under two parents’ plans.
Medicare Secondary Payer (MSP) Rules — Federal rules determining when Medicare pays second rather than first, such as when a patient has employer group health coverage through active employment, directly affecting how and to whom a lab must bill first.
National Correct Coding Initiative Policy Manual — The detailed CMS reference document explaining the clinical and coding rationale behind specific NCCI edits, useful for billing staff building an appeal when they believe an edit was applied incorrectly to a specific clinical scenario.
Signature on File — A provider or patient authorization, often standing rather than obtained per visit, permitting claims to be submitted and processed without a fresh signature for every single encounter, subject to periodic renewal requirements.
Medical Record Documentation Standard — The baseline standard requiring that clinical documentation actually support the codes billed, since a payer or auditor evaluating a claim looks first and foremost at whether the medical record substantiates the CPT and ICD-10 codes submitted, not merely whether the claim form was completed correctly.
A number of term pairs get confused often enough that they deserve to be called out directly, since the confusion itself is frequently what causes the downstream billing error:
EOB vs. ERA — one goes to the patient, one goes to the provider.
Denial vs. Rejection — timing and correction path differ completely.
CO vs. PR adjustment codes — one you can bill the patient for, one you legally cannot.
Medical necessity vs. clinical appropriateness — a test can be clinically appropriate and still fail a payer’s medical necessity policy for coverage purposes.
Modifier 59 vs. Modifier 91 — one unbundles distinct services, the other justifies a legitimate repeat test.
Referring lab vs. performing lab — Medicare generally requires the lab that actually performed the test to bill for it, not the lab that received the original order.
Presumptive vs. definitive drug testing — different methodologies, different codes, different medical necessity standards.
Upcoding vs. legitimate panel billing — billing a panel code correctly is compliant; billing components separately to increase reimbursement is not.
None of these terms exist in isolation, and that’s really the point of building a reference this thorough. A denial code only makes sense in light of the modifier that should have accompanied the original claim. An ABN only matters because of the medical necessity policy that made it necessary in the first place. A MolDx Z-Code only becomes relevant once you understand why Tier 1 and Tier 2 molecular codes exist at all. Laboratory billing terminology isn’t a list to memorize once and set aside; it’s a working vocabulary that gets sharper every time it’s applied against a real claim, a real denial, a real audit letter, or a real patient phone call.
Use this article as a resource during onboarding, denial review meetings, compliance training, or the next time a CARC code or an unfamiliar molecular billing term shows up that nobody on the team recognizes. Fluency across all ten domains is covered here with coding, claims processing, reimbursement mechanics, compliance, denial management, audits, patient financial responsibility, specimen workflow, technology, and specialty testing. This is what separates a billing department that reacts to problems from one that prevents them.